gene

HSP90AA1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about HSP90AA1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

731Connections

1Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

HSP90AA1 encodes Hsp90alpha, a molecular chaperone essential for protein folding and stability of client proteins including tau, alpha-synuclein, and LRRK2 in neurodegenerative diseases.

View on Wiki →

🧬 Gene Info

Gene Symbol	HSP90AA1
Full Name	Heat Shock Protein 90 Alpha Family Class A Member 1
Chromosome	14q32.31
Protein Type	Chaperone
Target Class	Chaperone
Function	Small molecule inhibitor binding to ATP-binding pocket of chaperone
Mechanism of Action	Small molecule inhibitor binding to ATP-binding pocket of chaperone
Druggability	Low (0.45)
Clinical Stage	Phase III
Molecular Weight	~90 kDa
Amino Acids	854 aa
Exons	11
Pathways	NF-κB
UniProt ID	P07900
NCBI Gene ID	3320
Ensembl ID	ENSG00000100425
OMIM	140571
GeneCards	HSP90AA1
Human Protein Atlas	HSP90AA1
Associated Diseases	ALS, Aging, Alzheimer, Alzheimer'S Disease
Known Drugs/Compounds	Chrysotoxine, Atbc, 17-Dmag, Nvp-Auy922, Nvp-Hsp990, Bisphenol F
Interactions	HSPA1A, DNAJB1, FKBP5, P38, LC3, APP
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	HSP90-Tau Disaggregation Complex Enhancement
KG Connections	731 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: HSP90AA1 — AlphaFold H0YJF5 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    HSP90AA1["HSP90AA1"]
    HSP90AA1 -->|"regulates"| HSP90_Tau_Disaggregation_Compl["HSP90-Tau Disaggregation Complex Enhancement"]
    HSP90AA1 -->|"target for"| Cancer["Cancer"]
    HSP90AA1 -->|"target for"| Fibrosis["Fibrosis"]
    HSP90AA1 -->|"inhibits"| Als["Als"]
    HSP90AA1 -->|"target for"| Ms["Ms"]
    HSP90AA1 -->|"target for"| Neuropathy["Neuropathy"]
    HSP90AA1 -->|"target for"| Carcinoma["Carcinoma"]
    h_637a53c9["h-637a53c9"] -->|"target for"| HSP90AA1
    h_0f00fd75["h-0f00fd75"] -->|"target for"| HSP90AA1
    HSPA1A["HSPA1A"] -->|"interacts"| HSP90AA1
    DNAJB1["DNAJB1"] -->|"interacts"| HSP90AA1
    FKBP5["FKBP5"] -->|"interacts"| HSP90AA1
    AKT["AKT"] -->|"target for"| HSP90AA1
    CASP3["CASP3"] -->|"target for"| HSP90AA1
    PI3K["PI3K"] -->|"target for"| HSP90AA1

Outgoing (461)

Target	Relation	Type	Str
Als	therapeutic_target	disease	0.95
Colorectal Cancer	involved_in	disease	0.90
ITGAV	activates	gene	0.90
ITGB5	interacts_with	gene	0.85
Cancer	therapeutic_target	disease	0.85
Als	activates	disease	0.85
HSPA1A	regulates	protein	0.80
Triple-Negative Breast Cancer	associated_with	disease	0.80
Client Proteins	regulates	protein	0.80
HSPB1	regulates	protein	0.80
Drug Resistance	contributes_to	phenotype	0.80
CASP3	therapeutic_target	gene	0.80
AKT	therapeutic_target	gene	0.80
protein_stability	enhances	molecular_function	0.80
Apoptosis	therapeutic_target	pathway	0.80
Mapk	therapeutic_target	pathway	0.80
CANCER	therapeutic_target	gene	0.80
Chrysotoxine	interacts_with	compound	0.75
Fibrosis	therapeutic_target	disease	0.75
Carcinoma	therapeutic_target	disease	0.75
Alzheimer	therapeutic_target	disease	0.75
HSP90-Tau Disaggregation Complex Enhancement	regulates	mechanism	0.70
ESR1	therapeutic_target	gene	0.70
JUN	therapeutic_target	gene	0.70
Complement	therapeutic_target	pathway	0.70
APOPTOSIS	therapeutic_target	gene	0.70
Apoptosis	activates	pathway	0.70
GENES	therapeutic_target	gene	0.70
MAPK signaling	participates_in	pathway	0.70
apoptosis pathway	participates_in	pathway	0.70
Als	inhibits	disease	0.65
Ms	therapeutic_target	disease	0.65
Neuropathy	therapeutic_target	disease	0.65
Ms	activates	disease	0.65
Tumor	associated_with	disease	0.65
Alzheimer	expressed_in	disease	0.65
Aging	expressed_in	disease	0.65
Als	expressed_in	disease	0.65
Ms	expressed_in	disease	0.65
Dementia	expressed_in	disease	0.65
Inflammation	therapeutic_target	disease	0.65
Tumor	therapeutic_target	disease	0.65
Ms	interacts_with	disease	0.65
Carcinoma	interacts_with	disease	0.65
Als	associated_with	disease	0.65
Ms	associated_with	disease	0.65
Leukemia	associated_with	disease	0.65
Cardiovascular	associated_with	disease	0.65
Ischemia	associated_with	disease	0.65
Cancer	expressed_in	disease	0.65

Incoming (270)

Source	Relation	Type	Str
17-Dmag	inhibits	drug	0.95
Nvp-Auy922	inhibits	drug	0.95
Nvp-Hsp990	inhibits	drug	0.95
17-DMAG	inhibits	drug	0.90
NVP-AUY922	inhibits	drug	0.90
NVP-HSP990	inhibits	drug	0.90
h-637a53c9	targets_gene	hypothesis	0.90
h-0f00fd75	targets_gene	hypothesis	0.90
h-ca454967	targets_gene	hypothesis	0.90
PI3K	therapeutic_target	gene	0.90
Atbc	binds	compound	0.85
Bisphenol F	binds	compound	0.85
h-637a53c9	targets	hypothesis	0.80
h-0f00fd75	targets	hypothesis	0.80
Chrysotoxine	targets	compound	0.80
AKT1	therapeutic_target	gene	0.80
CASP3	therapeutic_target	gene	0.70
MAPK3	therapeutic_target	gene	0.70
EGFR	therapeutic_target	gene	0.70
PI3K	regulates	gene	0.70
CASP3	targets	gene	0.70
BCL2	targets	gene	0.70
ESR1	targets	gene	0.70
ESR1	associated_with	gene	0.70
APOPTOSIS	therapeutic_target	gene	0.70
APOPTOSIS	activates	gene	0.70
HSPA1A	interacts_with	gene	0.61
DNAJB1	interacts_with	gene	0.61
FKBP5	interacts_with	gene	0.61
AKT	therapeutic_target	gene	0.60
JUN	therapeutic_target	gene	0.60
PTGS2	therapeutic_target	gene	0.60
HIF1A	therapeutic_target	gene	0.60
IGF1	therapeutic_target	gene	0.60
MMP9	therapeutic_target	gene	0.60
BCL2	therapeutic_target	gene	0.60
PARP1	therapeutic_target	gene	0.60
TNF	therapeutic_target	gene	0.60
CD4	therapeutic_target	gene	0.60
VEGF	therapeutic_target	gene	0.60
MYC	therapeutic_target	gene	0.60
MTOR	activates	gene	0.60
PI3K	activates	gene	0.60
AKT	activates	gene	0.60
FYN	expressed_in	gene	0.60
VCP	interacts_with	gene	0.60
CTNNB1	interacts_with	gene	0.60
EGFR	expressed_in	gene	0.60
TP53	therapeutic_target	gene	0.60
MTOR	therapeutic_target	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
HSP90-Tau Disaggregation Complex Enhancement	0.442	Alzheimer's Disease	Tau propagation mechanisms and therapeut

Mentioning Analyses (2)

Scientific analyses that reference this entity

Tau propagation mechanisms and therapeutic interception points

neurodegeneration | 2026-04-04 | 7 hypotheses Top: 0.487

APOE4 structural biology and therapeutic targeting strategies

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.595

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Gigantol: a principal bioactive constituent of Dendrobium species-multi-target m [PMID:40939944]	Shi S, Zhu C, Xu J, Sui Q, Zhu S, Zhang	Journal of ethnopharmacology	2026
Biomimetic cancer cell membrane-coated liposomal nanocarriers loaded with silibi [PMID:41585438]	Yao J, Sun Q, Zhang X, Yang D, Wu H et a	Mater Today Bio	2026
Exploring synergistic therapeutic potential of Erlotinib and artemisinin in non- [PMID:41672289]	Suleman F, Khan T, Alshehade SA, Ali M,	Clin Chim Acta	2026
Desidustat's cardioprotective mechanisms in heart failure: a network pharmacolog [PMID:41946767]	Sadiqbasha MF, Gunasekaran A, Thirulokac	Sci Rep	2026
PRMT5-Mediated Arginine Methylation of HSP90AA1 Drives Esophageal Squamous Cell [PMID:41966513]	Chen T, Lv Y, Wang J, Yuan Y, Xu K et al	Cancer Lett	2026
Methyl-4-hydroxybenzoate induces osteoporosis via the AKT1/LC3B/Beclin1 autophag [PMID:41740552]	Fu F, Wang W, Li Y, Shi S, Huang J, Liu	Ecotoxicology and environmenta	2026
Chronic Thermal Stress During Early Zebrafish (Danio rerio) Development Induces [PMID:41793424]	Adzijovski M, Schultz AG, Oxley APA, Ber	Fish physiology and biochemist	2026
α-Glucosidase inhibitor: identifying key targets and mechanisms in type 2 diabet [PMID:41907120]	Garg SS, Vijh D, Gupta P, Gupta J, Malik	3 Biotech	2026
Elucidating the mechanisms of aristolochic acid-induced upper tract urothelial c [PMID:41780445]	Liu T, Yao Y, Xu Y, Zhang H, Sun L, Zhan	Computational biology and chem	2026
A Study on the Mechanism of Acetyl Tributyl Citrate-Induced Infertility Toxicity [PMID:41898778]	Sun X, Chen P, Han Y, Du Y, Sun S, Miu J	International journal of molec	2026
Investigating the clinical efficacy, safety and molecular mechanism of sulforaph [PMID:41275316]	Long J, Liao X, Tang Z, Han K, Chen J, W	BMC pharmacology & toxicology	2025
Cerebrospinal fluid HSP90AA1, HSPA4, and STUB1/CHIP levels in Alzheimer's diseas [PMID:40116694]	Sordu P, Alaylıoğlu M, Samancı B, Bulu E	J Alzheimers Dis	2025
The chaperones HSP90AA1, HSP90AB1 and BAG3 are specifically distributed among hu [PMID:40436281]	Soriano-Herrador C, Ubeda-Banon I, Villa	Neurobiol Dis	2025
Mapping the pathogenic nexus: Gene overlap and protein interaction networks in A [PMID:40973403]	Chowdhury MR, Deepa VS, Raja VK	Adv Protein Chem Struct Biol	2025
The mechanism of probiotics in pregnancy outcomes in overweight or obese pregnan [PMID:40859213]	Zhong T, Sun J, Miao M, Sun G	BMC pregnancy and childbirth	2025
Chrysotoxine regulates ferroptosis and the PI3K/AKT/mTOR pathway to prevent cerv [PMID:39557107]	Zhou J, Guo Z, Peng X, Wu B, Meng Q, Lu	Journal of ethnopharmacology	2025
A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execut [PMID:38261660]	Iskandar K, Foo J, Liew AQX, Zhu H, Rama	Autophagy	2024
Proteomic analysis identifies HSP90AA1, PTK2B, and ANXA2 in the human entorhinal [PMID:38247340]	Astillero-Lopez V, Villar-Conde S, Gonza	Brain pathology (Zurich, Switz	2024
Efficient analysis of toxicity and mechanisms of environmental pollutants with n [PMID:37858827]	Huang S	The Science of the total envir	2023
Regulation of TFEB nuclear localization by HSP90AA1 promotes autophagy and longe [PMID:35941759]	Yang S, Nie T, She H, Tao K, Lu F et al.	Autophagy	2023

HSP90AA1

Understanding Entity Pages

Summary

Wiki Pages (21)

HSP90AA1 Gene

cbs-psp-daily-action-plan

Prion vs Tau/Alpha-Synuclein Propagation: Mechanistic Comparison

Oligodendrocyte and Myelin Dysfunction in Corticobasal Syndrome

Proteostasis Network Dysfunction Comparison Across Neurodegenerative Diseases

Granulovacuolar Bodies: Neuronal Defense Mechanism Against Tau Pathology

Shared Proteinostasis Failure in Alzheimer's and Parkinson's Disease

Section 189: Advanced Autophagy-Endolysosomal Pathway Therapy in CBS/PSP

Tau Proteostasis and Clearance Across 4R-Tauopathies

proteostasis-triad-pulses

Chaperone-Mediated Proteostasis Disease Comparison

chaperone-mediated-autophagy-parkinsons

oga-inhibition-tau

Gosuranemab (BIIB092)

Section 102: Proteostasis Network Dysregulation in CBS/PSP

Proteostasis Therapy CBS PSP

Proteostasis Network in Neurodegeneration

Tau Propagation Mechanisms

Tau-PROTAC Heterobifunctional Degrader for Tauopathy

Hsp70/Hsp90 Chaperone Pathway in Parkinson's Disease

Section 204: Advanced Proteostasis and Protein Quality Control in CBS/PSP